Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
Open Access
- 18 April 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 12 (7), 1067-1076
- https://doi.org/10.1002/lt.20737
Abstract
There are unresolved issues regarding sustained virological response (SVR), tolerance and risk of rejection following antiviral therapy in liver transplantation (LT). The aim of our study was to determine efficacy, rejection risk and factors associated with SVR. HCV-infected LT patients with at least 6 months of follow-up following end-of-therapy (EOT) received combination therapy of ribavirin (Rbvr) + standard (n=31)/pegIFN (n=36) between 1999 and 2004 (95% genotype 1). An EOT and SVR was obtained in 46% and 33%, respectively. Type of antiviral therapy, use of erythropoietin, compliance, and early virologic response (EVR) were predictive of SVR, but only the latter remained in the multivariate analysis. Premature discontinuation, not impacted by the use of erythropoietin or GCSF, occurred in 40% patients. None of the variables predicted rejection (acute n=2, chronic n=4). A SVR occurred in 3/4 patients with chronic rejection. In conclusion, the efficacy of pegIFN-Rbvr is similar to the non-transplant population. An EVR at 3 months is useful to predict lack of response. The type of calcineurin inhibitor and history of prior non-response to IFN before LT do not influence the outcome of therapy. Severe rejection may lead to graft loss, a complication difficult to predict. Liver Transpl 12:1067–1076, 2006. © 2006 AASLD.Keywords
This publication has 26 references indexed in Scilit:
- Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantationJournal of Hepatology, 2005
- Comparison of Qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and Quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) Assays for Hepatitis C Virus (HCV) RNA Detection and Quantification: Impact on Diagnosis and Treatment of HCV InfectionsJournal of Clinical Microbiology, 2005
- Hepatitis C after liver transplantation: risk factors, outcomes, and treatmentCurrent Opinion in Organ Transplantation, 2005
- Recurrent hepatitis C genotype 1b following liver transplantationEuropean Journal of Gastroenterology & Hepatology, 2004
- Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantationLiver Transplantation, 2004
- Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combinationJournal of Hepatology, 2004
- Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaLiver Transplantation, 2004
- Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-upTransplantation, 2004
- Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on liver transplantation and hepatitis CLiver Transplantation, 2003
- High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodesHepatology, 1999